BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A...
BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A...
BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A Peer-Reviewed Article Entitled, "H-Coil Repetitive Transcranial Magnetic Stimulation Relieves Pain And Symptoms Of Anxiety And Depression In Patients With Chronic Peripheral Neuropathic Pain: A Randomized Sham-Controlled Crossover Study."
BrainsWay宣布发表了一项可行性临床数据评估,研究了深部经颅磁刺激对患有外周神经病性疼痛的患者的镇痛效果。结果已发表在《神经调控杂志》上,题为“H-线圈重复经颅磁刺激缓解慢性外周神经病性疼痛患者的疼痛和焦虑抑郁症状:一项随机安慰剂对照交叉研究”中。
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of positive feasibility clinical data evaluating the analgesic effects of deep transcranial magnetic stimulation (Deep TMS) in patients with peripheral neuropathic pain. The results were published in the Neuromodulation journal, in a peer-reviewed article entitled, "H-Coil Repetitive Transcranial Magnetic Stimulation Relieves Pain and Symptoms of Anxiety and Depression in Patients with Chronic Peripheral Neuropathic Pain: A Randomized Sham-Controlled Crossover Study."
BrainsWay股份有限公司(纳斯达克和以色列证券交易所:BWAY)(“BrainsWay”或“公司”),全球领先的先进非侵入性神经刺激治疗技术的领导者,今天宣布发表了评估深部经颅磁刺激(Deep TMS)对患有外周神经病性疼痛的患者的镇痛效果的积极可行性临床数据。结果已发表在《神经调控杂志》上,题为“H-线圈重复经颅磁刺激缓解慢性外周神经病性疼痛患者的疼痛和焦虑抑郁症状:一项随机安慰剂对照交叉研究”中。
The double-blind, randomized crossover trial included seventeen (17) patients with chronic neuropathic pain. Participants were assigned to either an active Deep TMS or sham treatment arm for a five-day period, followed by a nine-week washout, before crossing over to the other arm. The study's primary outcome measure was a comparison between the patterns of the active and sham groups' self-reported changes in pain levels from baseline. Secondary outcomes included changes in pain ratings at specific time points in the two arms, as well as changes in comorbid symptoms experienced by the patients, including, for example, anxiety and depression.
这项双盲、随机交叉试验包括十七(17)名慢性神经病性疼痛患者。参与者被分配到为期五天的积极Deep TMS或安慰剂治疗组,随后进行九周停药期,然后交叉到另一个治疗组。研究的主要结果指标是积极组和安慰剂组基线下疼痛水平的自我报告变化模式的比较。次要结果包括两个治疗组在特定时间点的疼痛评分变化,以及患者经历的共患症状变化,例如焦虑和抑郁。
Results showed that Active deep-TMS therapy significantly reduced "usual pain intensity" in patients with chronic peripheral neuropathic pain compared to sham treatment and improved symptoms of anxiety and depression in the same patient population.
结果显示,积极的深部TMS疗法显著降低了慢性外周神经病性疼痛患者的“一般性疼痛强度”,与安慰剂治疗相比,并改善了同一患者群体的焦虑和抑郁症状。